Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (71-80 of 484) with videos related to

Pageof 49
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Evolving Recommendations on Prostate Cancer ScreeningOtis W Brawley, Ian M Thompson, Henrik Grönberg
JAMA Internal Medicine|October 8, 2019
5α-Reductase Inhibitor Use in Patients With Prostate CancerIan M Thompson, Catherine M Tangen, Barnett Kramer
The Urologic Clinics of North America|May 5, 2004
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditionsJavier Hernandez, Joseph W Basler, Ian M Thompson
Urologic Oncology|June 18, 2003
Management of high-risk localized prostate cancer: the integration of local and systemic therapy approachesSamira Syed, Daniel P Petrylak, Ian M Thompson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2005
Prevention of hormone-related cancers: prostate cancerHoward L Parnes, Ian M Thompson, Leslie G Ford
The Journal of Urology|November 7, 2006
Recommendations for defining and treating high risk localized prostate cancerIan M Thompson, Peter R Carroll, Michael A Carducci
Journal of the National Cancer Institute|August 21, 2010
Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigmaIan M Thompson, Donna P Ankerst, Catherine M Tangen
Journal of the National Cancer Institute|March 22, 2007
Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curabilityRuth D Etzioni, Donna P Ankerst, Ian M Thompson
Journal of the National Cancer Institute|April 5, 2007
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studiesDipen J Parekh, Donna P Ankerst, Ian M Thompson
International Journal of Epidemiology|April 25, 2007
Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9Ian M Thompson, M Scott Lucia, Catherine M Tangen
Pageof 49

Showing results (71-80 of 484) with videos related to

Sort By:
Pageof 49
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Evolving Recommendations on Prostate Cancer ScreeningOtis W Brawley, Ian M Thompson, Henrik Grönberg
JAMA Internal Medicine|October 8, 2019
5α-Reductase Inhibitor Use in Patients With Prostate CancerIan M Thompson, Catherine M Tangen, Barnett Kramer
The Urologic Clinics of North America|May 5, 2004
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditionsJavier Hernandez, Joseph W Basler, Ian M Thompson
Urologic Oncology|June 18, 2003
Management of high-risk localized prostate cancer: the integration of local and systemic therapy approachesSamira Syed, Daniel P Petrylak, Ian M Thompson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2005
Prevention of hormone-related cancers: prostate cancerHoward L Parnes, Ian M Thompson, Leslie G Ford
The Journal of Urology|November 7, 2006
Recommendations for defining and treating high risk localized prostate cancerIan M Thompson, Peter R Carroll, Michael A Carducci
Journal of the National Cancer Institute|August 21, 2010
Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigmaIan M Thompson, Donna P Ankerst, Catherine M Tangen
Journal of the National Cancer Institute|March 22, 2007
Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curabilityRuth D Etzioni, Donna P Ankerst, Ian M Thompson
Journal of the National Cancer Institute|April 5, 2007
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studiesDipen J Parekh, Donna P Ankerst, Ian M Thompson
International Journal of Epidemiology|April 25, 2007
Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9Ian M Thompson, M Scott Lucia, Catherine M Tangen
Pageof 49